Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 7, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Market Capitalization	20,860	22,569	21,573	20,525	33,154	44,361
Market Cap Growth	-7.09%	4.62%	5.11%	-38.09%	-25.26%	68.38%
Enterprise Value	22,904	24,170	23,045	20,899	31,905	43,858
Last Close Price	49.58	53.76	51.15	48.82	78.66	105.47
PE Ratio	68.82	56.06	61.99	141.14	86.55	73.16
Forward PE	27.11	29.63	42.25	65.91	49.20	99.01
PS Ratio	6.39	7.80	8.78	8.64	14.76	23.72
PB Ratio	3.52	3.98	4.03	4.14	7.08	10.70
P/TBV Ratio	7.67	9.47	7.45	6.38	11.18	14.20
P/FCF Ratio	444.02	270.04	-	-	-	-
P/OCF Ratio	27.88	24.77	23.60	66.91	62.96	68.67
PEG Ratio	-	3.08	3.08	3.08	3.08	3.08
EV/Sales Ratio	7.02	8.36	9.38	8.79	14.21	23.45
EV/EBITDA Ratio	24.19	28.60	39.86	46.08	61.61	76.95
EV/EBIT Ratio	43.84	50.68	82.34	100.98	91.48	105.74
EV/FCF Ratio	487.53	289.20	-	-	-	-
Debt / Equity Ratio	0.42	0.42	0.45	0.21	0.00	0.00
Debt / EBITDA Ratio	2.60	2.82	4.17	2.27	0.02	0.00
Debt / FCF Ratio	52.36	28.67	-	-	-	-
Asset Turnover	0.34	0.31	0.29	0.34	0.39	0.40
Inventory Turnover	2.16	1.74	1.16	0.81	0.72	0.86
Quick Ratio	0.44	0.38	0.58	0.59	1.36	3.64
Current Ratio	0.77	0.66	0.85	0.82	1.86	4.22
Return on Equity (ROE)	4.89%	7.03%	6.47%	2.59%	8.60%	18.18%
Return on Assets (ROA)	3.43%	3.23%	2.05%	1.82%	3.79%	5.54%
Return on Capital (ROIC)	3.97%	3.76%	2.54%	2.42%	4.93%	7.14%
Return on Capital Employed (ROCE)	6.70%	6.40%	3.80%	3.60%	6.50%	8.70%
Earnings Yield	1.45%	1.78%	1.61%	0.71%	1.16%	1.37%
FCF Yield	0.23%	0.37%	-0.84%	-3.43%	-0.70%	-0.09%
Dividend Yield	0.40%	0.37%	0.33%	0.14%	0.32%	0.29%
Payout Ratio	60.29%	37.48%	31.69%	95.94%	35.93%	19.74%
Buyback Yield / Dilution	0.15%	-0.01%	-0.72%	0.02%	-2.32%	-1.09%
Total Shareholder Return	0.56%	0.37%	-0.39%	0.16%	-2.00%	-0.80%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.